Blake Wise, Novome Biotechnologies CEO

Genen­tech-part­nered Novome lands $43.5M to push gas­troin­testi­nal drug through mid-stage study

A biotech with con­nec­tions to Roche’s Genen­tech has now land­ed its newest cash in­fu­sion.

Mi­cro­bio­me out­fit Novome Biotech­nolo­gies said Tues­day that it has now se­cured $43.5 mil­lion in new fi­nanc­ing via a Se­ries B round. The funds, ac­cord­ing to the com­pa­ny, will be used to ad­vance its lead can­di­date through an on­go­ing Phase IIa — and ad­vance oth­er can­di­dates for a po­ten­tial in­di­ca­tion in in­flam­ma­to­ry bow­el dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.